Diagnostic test | Sensitivity | Specificity | Positive predictive value | Negative predictive value |
---|---|---|---|---|
General population | ||||
Pre-treatment combined gold standarda | ||||
Kato Katz | 64.7% (95%CI:59.6–69.5) | 100% (95%CI:92.1–100) | 100% (95%CI:98.5–100) | 25.4% (19.2–32.5) |
Post-treatment combined gold standarda | ||||
Kato Katz | 35.6% (95%CI:24.7–47.7) | 100% (95%CI:97.4–100) | 100 (95%CI:86.8–100) | 74.7% (95%CI:67.9–80.8) |
In the HIV-1 seropositive group | ||||
Pre-treatment combined gold standarda | ||||
Kato Katz | 60% (95%CI:38.7–78.9) | 100% (95%CI:39.8–100) | 100% (95%CI:78.2–100) | 28.6% (95%CI:8.4–58.1) |
Post-treatment combined gold standarda | ||||
Kato Katz | 33.3% (95%CI:43–77.7) | 100% (95%CI:59–100) | 100% (95%CI:15.8–100) | 63.6% (95%CI:30.8–89.1) |